Development of (177)Lu-phytate Complex for Radiosynovectomy

Area of Science:

• Nuclear medicine
• Radiopharmaceutical chemistry
• Oncology and Rheumatology

Background:

• Radiosynovectomy is a treatment for inflammatory joint diseases.
• New radiolabeled agents are needed for effective articular pain palliation.

Purpose of the Study:

• To develop and evaluate a new Lutetium-177 phytate complex for radiosynovectomy.
• To assess the feasibility of this agent for articular pain management.

Main Methods:

• Lutetium-177 (Lu-177) was produced and labeled onto a phytate complex.
• Radiochemical purity was assessed using Instant Thin-Layer Chromatography (ITLC).
• The complex was injected intra-articularly into rat knee joints to evaluate retention and distribution.

Main Results:

• The Lu-177 phytate complex was prepared with high radiochemical purity (>99.9%).
• The injected dose remained localized at the injection site for up to seven days post-injection.
• No significant leakage or distribution to other organs was observed.

Conclusions:

• The Lu-177 phytate complex is a stable and effective agent for radiosynovectomy.
• This agent shows potential for cavitary radiotherapy in oncology and rheumatology for pain palliation.